Get the Stockscreener App
131.14
1.57%
2.03
After Hours:
131.96
0.82
+0.63%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $131.14, with a volume of 8.55M.
It is up +1.57% in the last 24 hours and up +5.62% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$129.11
Open:
$129.13
24h Volume:
8.55M
Relative Volume:
1.24
Market Cap:
$162.70B
Revenue:
$29.05B
Net Income/Loss:
$8.11B
P/E Ratio:
20.31
EPS:
6.4563
Net Cash Flow:
$9.16B
1W Performance:
+8.15%
1M Performance:
+5.62%
6M Performance:
+19.03%
1Y Performance:
+40.95%
1-Day Range:
$129.00
$133.10
1-Week Range:
$122.10
$133.10
52-Week Range:
$92.21
$133.10
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
131.14 | 160.18B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,087.38 | 965.30B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.49 | 525.25B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
218.11 | 382.02B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.00 | 278.44B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.23 | 263.59B | 46.69B | 15.29B | 9.25B | 3.4329 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer - GlobeNewswire Inc.
Gilead Sciences publishes Trodelvy-Keytruda data in NEJM - The Pharma Letter
Cell Therapy Market Dynamics and Contributions by Gilead - openPR.com
Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen - Chartmill
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
GILD: Gilead Sciences Reports Positive Results for Trodelvy and Keytruda Combo - GuruFocus
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Gilead Sciences stock hits all-time high at 128.71 USD By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at 128.71 USD - Investing.com
Rothschild & Co Redburn Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness - Yahoo Finance New Zealand
Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Gilead Sciences, Inc. $GILD - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
US Stocks Recap: What is the PEG ratio of Gilead Sciences IncPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced (NASDAQ:GILD) - Seeking Alpha
The Truth About Gilead Sciences Inc: Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Bernstein reiterates Outperform rating on Gilead stock with $135 price target - Investing.com
Gilead Sciences, Inc. $GILD Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
40 Under 40: Calvin Yan Ting Chan, Gilead Sciences - Medical Marketing and Media
Stocks Generating Improved Relative Strength: Gilead Sciences - Investor's Business Daily
Gilead Sciences Earnings Outlook: Key Points to Watch - Bitget
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Gilead Sciences Earnings Preview: What to Expect - Barchart.com
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Allstate Corp Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Nasdaq Futures Spotlight Biopharma Scale - Kalkine Media
Csenge Advisory Group Has $2.38 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Campbell & CO Investment Adviser LLC Invests $1.40 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by QRG Capital Management Inc. - MarketBeat
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - Barchart.com
Insider Sell: Andrew Dickinson Sells 3,000 Shares of Gilead Scie - GuruFocus
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Stock - MarketBeat
Gilead Sciences CCO Mercier sells $372,930 in stock - Investing.com
Gilead Sciences CFO Dickinson sells $372,930 in stock - Investing.com India
The Truth About Gilead Sciences: Is This ‘Boring’ Pharma Stock About To Blow Up? - AD HOC NEWS
Hedge Fund Moves: Whats the analyst consensus on Gilead Sciences IncWeekly Profit Recap & Fast Gain Stock Tips - baoquankhu1.vn
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade) (NASDAQ:GILD) - Seeking Alpha
Looking Into Gilead Sciences Inc's Recent Short Interest - Benzinga
Gilead Sciences, Inc. $GILD Shares Purchased by Ritholtz Wealth Management - MarketBeat
GILD Stock Price, Forecast & Analysis | GILEAD SCIENCES INC (NASDAQ:GILD) - Chartmill
Short Covering: Is GCTSWS stock a good pick for beginnersJuly 2025 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn
Gilead stock holds Buy rating at UBS as Yeztugo launch shows promise - Investing.com
Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc. - MarketBeat
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes - BioSpace
Gilead Sciences, Inc. (GILD) Stock Analysis: Strong Buy Ratings and 10.84% Potential Upside - DirectorsTalk Interviews
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Manning & Napier Advisors LLC Has $13.65 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CFO Andrew Dickinson sells $14 million in stock - MSN
A Look At Gilead Sciences (GILD) Valuation After JP Morgan Conference HIV Pipeline Update - Sahm
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):